Search This Blog

Tuesday, March 3, 2026

Amylyx advances avexitide Phase III, targets 2027 launch with cash runway into 2028

 as Q4 non-GAAP EPS improves to -$0.30

  • LUCIDITY Phase III in PBH fully recruited; last patient dosing expected this month.
  • Top-line LUCIDITY data guided for Q3 2026, underpinning a potential first PBH NDA.
  • Commercial and medical infrastructure ramping for possible 2027 avexitide launch in a large orphan PBH market.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)